A wide varieties of malignancies have been reported with increasing incidence among SOT (solid organ transplantation) patients.

DEVELOPMENT OF MALIGNANCY FOLLOWING SOLID ORGAN TRANSPLANTATION

A wide varieties of malignancies have been reported with increasing incidence among SOT (solid organ transplantation) patients. The reported incidence of certain malignancy seems to be related to the type of the transplanted organ. Many risk factors have been related to the increasing incidence of secondary malignancy among organ transplant recipients that may include sun ray’s exposure, potency and longevity of immunosuppression, associated viral infection, and particularly in KTRs (kidney transplant recipients), pre-transplant dialysis.  

 

 

Role of the immunosuppressive agents

Certain evidence suggests that CNI (calcineurin inhibitors) and azathioprine, but not sirolimus may trigger certain risk for cancer development that could be out of the impact of potency and duration of immunosuppression. However, sirolimus, in comparison to other immunosuppressive agents, may confer a lowered risk of cancer evolution. In regard to virology prevalence, 4 culprit viruses may be involved (cocarcinogenic viruses) in organ transplant recipients (TR) that include Epstein-Barr virus (EBV), HHV-8, human papillomavirus (HPV), and the Merkel cell polyomavirus (MCV).